Peter Peneder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Peter Peneder has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Eleni M. Tomazou
St. Anna Children’s Cancer Research Institute (CCRI), Vienna, Austria
14 shared publications Markus Metzler
12 shared publications- Uta Dirksen
University Hospital Essen
12 shared publications Abbas Agaimy
11 shared publicationsAdrian M Stütz
11 shared publicationsAndreas Ranft
11 shared publications
Latest Publications
- 4 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53 , STAG2 , and CDKN2A Alterations
PURPOSE: Ewing sarcoma is an aggressive bone cancer driven by FET::ETS fusions, with few recurrent secondary genomic alterations (most commonly involving STAG2 , TP53 , and CDKN2A ) and copy-number variants. Currently, diagnosis relies exclusively on tumor biopsies and imaging, and despite a well-defined genomic landscape, risk stratification remains based solely on clinicoradiologic parameters. Furthermore, tumor evolution and intrapatient heterogeneity remain poorly characterized, and prospective evidence supporting molecular risk stratification is limited. MATERIALS AND METHODS: We prospectively integrated serial circulating tumor DNA (ctDNA) sampling into the first-line phase II/III Euro Ewing 2012 (EE2012) and CombinaiR3 trials, complemented by relapse studies. Across 347 patients, 991 blood, tumor, and bone marrow samples were profiled using custom targeted sequencing and shallow whole-genome sequencing to enable integrated biologic characterization and clinical correlative analyses. RESULTS: ctDNA recapitulated established Ewing sarcoma genomic landscapes while also revealing intrapatient tumor heterogeneity when compared with matched tumor biopsy profiles. Blood and bone marrow plasma profiles were highly concordant. Longitudinal sampling identified selection of TP53 -altered clones at relapse. Clinically, detection of TP53 and/or STAG2 loss-of-function mutations and/or CDKN2A focal deletions in ctDNA at diagnosis predicted poor outcomes and, in a multivariable model adjusting for metastatic status, tumor volume, age, and treatment, defined an independent molecular high-risk subgroup with inferior event-free survival (hazard ratio [HR], 3.6 [95% CI, 2.2 to 5.8], P < .001) and overall survival (HR, 4.3 [95% CI, 2.5 to 7.3], P < .001) in EE2012 patients. CONCLUSION: Prospective, trial-integrated ctDNA profiling provides comprehensive molecular characterization, reveals clinically relevant heterogeneity and clonal evolution, and identifies an independent molecular high-risk subgroup at diagnosis, supporting ctDNA-guided risk stratification in Ewing sarcoma.
- 4 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53 , STAG2 , and CDKN2A Alterations
PURPOSE: Ewing sarcoma is an aggressive bone cancer driven by FET::ETS fusions, with few recurrent secondary genomic alterations (most commonly involving STAG2 , TP53 , and CDKN2A ) and copy-number variants. Currently, diagnosis relies exclusively on tumor biopsies and imaging, and despite a well-defined genomic landscape, risk stratification remains based solely on clinicoradiologic parameters. Furthermore, tumor evolution and intrapatient heterogeneity remain poorly characterized, and prospective evidence supporting molecular risk stratification is limited. MATERIALS AND METHODS: We prospectively integrated serial circulating tumor DNA (ctDNA) sampling into the first-line phase II/III Euro Ewing 2012 (EE2012) and CombinaiR3 trials, complemented by relapse studies. Across 347 patients, 991 blood, tumor, and bone marrow samples were profiled using custom targeted sequencing and shallow whole-genome sequencing to enable integrated biologic characterization and clinical correlative analyses. RESULTS: ctDNA recapitulated established Ewing sarcoma genomic landscapes while also revealing intrapatient tumor heterogeneity when compared with matched tumor biopsy profiles. Blood and bone marrow plasma profiles were highly concordant. Longitudinal sampling identified selection of TP53 -altered clones at relapse. Clinically, detection of TP53 and/or STAG2 loss-of-function mutations and/or CDKN2A focal deletions in ctDNA at diagnosis predicted poor outcomes and, in a multivariable model adjusting for metastatic status, tumor volume, age, and treatment, defined an independent molecular high-risk subgroup with inferior event-free survival (hazard ratio [HR], 3.6 [95% CI, 2.2 to 5.8], P < .001) and overall survival (HR, 4.3 [95% CI, 2.5 to 7.3], P < .001) in EE2012 patients. CONCLUSION: Prospective, trial-integrated ctDNA profiling provides comprehensive molecular characterization, reveals clinically relevant heterogeneity and clonal evolution, and identifies an independent molecular high-risk subgroup at diagnosis, supporting ctDNA-guided risk stratification in Ewing sarcoma.
- Top Cited PapersOpen Access
- 11 November 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 44 (10) , 1-11
Multimodal learning enables chat-based exploration of single-cell data
Single-cell sequencing characterizes biological samples at unprecedented scale and detail, but data interpretation remains challenging. Here, we present CellWhisperer, an artificial intelligence (AI) model and software tool for chat-based interrogation of gene expression. We establish a multimodal embedding of transcriptomes and their textual annotations, using contrastive learning on 1 million RNA sequencing profiles with AI-curated descriptions. This embedding informs a large language model that answers user-provided questions about cells and genes in natural-language chats. We benchmark CellWhisperer’s performance for zero-shot prediction of cell types and other biological annotations and demonstrate its use for biological discovery in a meta-analysis of human embryonic development. We integrate a CellWhisperer chat box with the CELLxGENE browser, allowing users to interactively explore gene expression through a combined graphical and chat interface. In summary, CellWhisperer leverages large community-scale data repositories to connect transcriptomes and text, thereby enabling interactive exploration of single-cell RNA-sequencing data with natural-language chats.
- 11 November 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 44 (10) , 1-11
Top Cited PapersOpen AccessMultimodal learning enables chat-based exploration of single-cell data
Single-cell sequencing characterizes biological samples at unprecedented scale and detail, but data interpretation remains challenging. Here, we present CellWhisperer, an artificial intelligence (AI) model and software tool for chat-based interrogation of gene expression. We establish a multimodal embedding of transcriptomes and their textual annotations, using contrastive learning on 1 million RNA sequencing profiles with AI-curated descriptions. This embedding informs a large language model that answers user-provided questions about cells and genes in natural-language chats. We benchmark CellWhisperer’s performance for zero-shot prediction of cell types and other biological annotations and demonstrate its use for biological discovery in a meta-analysis of human embryonic development. We integrate a CellWhisperer chat box with the CELLxGENE browser, allowing users to interactively explore gene expression through a combined graphical and chat interface. In summary, CellWhisperer leverages large community-scale data repositories to connect transcriptomes and text, thereby enabling interactive exploration of single-cell RNA-sequencing data with natural-language chats.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Composition of the study groups with a good histological response and poor histological response with regard to tumor volume, presence of metastases, and osseous localization.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Composition of the study groups with a good histological response and poor histological response with regard to tumor volume, presence of metastases, and osseous localization.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Event-free survival (EFS) and overall survival (OS) by sex, age at diagnosis, pelvis localization, tumor volume, presence of metastases, and histological response in patients with EWS.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Event-free survival (EFS) and overall survival (OS) by sex, age at diagnosis, pelvis localization, tumor volume, presence of metastases, and histological response in patients with EWS.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Event-free survival (EFS) and overall survival (OS) by quantified pretreatment ctDNA levels for patients with localized or metastatic disease.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Event-free survival (EFS) and overall survival (OS) by quantified pretreatment ctDNA levels for patients with localized or metastatic disease.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Event-free survival (EFS) and overall survival (OS) by quantified pretreatment ctDNA levels for patients with localized or metastatic disease.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Event-free survival (EFS) and overall survival (OS) by quantified pretreatment ctDNA levels for patients with localized or metastatic disease.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Event-free survival (EFS) and overall survival (OS) by sex, age at diagnosis, pelvis localization, tumor volume, presence of metastases, and histological response in patients with EWS.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Event-free survival (EFS) and overall survival (OS) by sex, age at diagnosis, pelvis localization, tumor volume, presence of metastases, and histological response in patients with EWS.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Quantified mean ctDNA levels (fusion gene/ALB copies) before (VIDE1A) and after (VIDE1E) the first chemotherapy block separated according to different clinical risk criteria. The upper graphs show results for localized disease, the lower graphs show results for metastatic disease.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Quantified mean ctDNA levels (fusion gene/ALB copies) before (VIDE1A) and after (VIDE1E) the first chemotherapy block separated according to different clinical risk criteria. The upper graphs show results for localized disease, the lower graphs show results for metastatic disease.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Quantified mean ctDNA levels (fusion gene/ALB copies) before (VIDE1A) and after (VIDE1E) the first chemotherapy block separated according to different clinical risk criteria. The upper graphs show results for localized disease, the lower graphs show results for metastatic disease.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Quantified mean ctDNA levels (fusion gene/ALB copies) before (VIDE1A) and after (VIDE1E) the first chemotherapy block separated according to different clinical risk criteria. The upper graphs show results for localized disease, the lower graphs show results for metastatic disease.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Purpose:We evaluated the predictive and prognostic value of circulating tumor DNA (ctDNA) in patients with Ewing sarcoma (EWS) treated in the EWING2008 trial.Experimental Design:Plasma samples from 102 patients with EWS enrolled in the EWING2008 trial were obtained before and during induction chemotherapy. Genomic EWSR1 fusion sequence spanning primers and probes were used for highly specific and sensitive quantification of the levels of ctDNA by digital droplet PCR. ctDNA levels were correlated to established clinical risk factors and outcome parameters.Results:Pretreatment ctDNA copy numbers were correlated with event-free and overall survival. The reduction in ctDNA levels below the detection limit was observed in most cases after only two blocks of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) induction chemotherapy. The persistence of ctDNA after two VIDE blocks was a strong predictor of poor outcomes. ctDNA levels correlated well with most established clinical risk factors; an inverse correlation was found only for the histologic response to induction therapy. ctDNA levels did not provide simple representations of tumor volume, but integrated information from various tumor characteristics represented an independent EWS tumor marker with predictive and prognostic value.Conclusions:ctDNA copy number in the plasma of patients with EWS is a quantifiable parameter for early risk stratification and can be used as a dynamic noninvasive biomarker for early prediction of treatment response and outcome of patients.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Purpose:We evaluated the predictive and prognostic value of circulating tumor DNA (ctDNA) in patients with Ewing sarcoma (EWS) treated in the EWING2008 trial.Experimental Design:Plasma samples from 102 patients with EWS enrolled in the EWING2008 trial were obtained before and during induction chemotherapy. Genomic EWSR1 fusion sequence spanning primers and probes were used for highly specific and sensitive quantification of the levels of ctDNA by digital droplet PCR. ctDNA levels were correlated to established clinical risk factors and outcome parameters.Results:Pretreatment ctDNA copy numbers were correlated with event-free and overall survival. The reduction in ctDNA levels below the detection limit was observed in most cases after only two blocks of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) induction chemotherapy. The persistence of ctDNA after two VIDE blocks was a strong predictor of poor outcomes. ctDNA levels correlated well with most established clinical risk factors; an inverse correlation was found only for the histologic response to induction therapy. ctDNA levels did not provide simple representations of tumor volume, but integrated information from various tumor characteristics represented an independent EWS tumor marker with predictive and prognostic value.Conclusions:ctDNA copy number in the plasma of patients with EWS is a quantifiable parameter for early risk stratification and can be used as a dynamic noninvasive biomarker for early prediction of treatment response and outcome of patients.